

EP Equity Investment and Nanobacterie Announce Strategic Partnership with 24.99% Stake Acquisition

EP Equity Investment (EPEI), the investment company focused on promising European businesses (separate from EP Group's industrial holdings, energy, logistics, or media assets), and **Nanobacterie** are thrilled to announce a significant new partnership. Through this collaboration, EPEI has acquired a 24.99% stake in Nanobacterie.

This partnership marks a pivotal step for Nanobacterie as it advances the development of its groundbreaking medical device for treating prostate cancer. Nanobacterie is dedicated to revolutionizing prostate cancer treatment through cutting-edge research and development. The company has created a unique treatment method and device, now poised for the next phase of clinical trials and regulatory approvals.

Investing in Nanobacterie aligns perfectly with EPEI commitment to supporting companies at the forefront of medical innovation. EPEI is highly impressed by Nanobacterie's novel treatment solutions and is dedicated to supporting their journey through clinical approvals, ultimately aiming to improve patient outcomes in prostate cancer treatment.

Edouard Alphanféry, founder of Nanobacterie, expressed his gratitude for the collaboration: "EPEI's investment is critical for us at this crucial stage of development. Their belief in our mission and technology allows us to move forward with the essential clinical trials needed to bring our treatment to patients. Together, we are setting a new standard in cancer treatment."

Nanobacterie, a pioneering startup, develops a non-invasive cancer treatment utilizing magnetic nanoparticles synthesized by magnetotactic bacteria. Founded in 2008 by Dr. Edouard Alphanféry, a renowned international expert in oncological hyperthermia, Nanobacterie's team has been diligently developing a treatment method and medical devices for prostate cancer, with potential applications for other conditions. The company is currently gearing up for clinical trials and subsequent commercialization of their products.

EP Equity Investment is an investment firm specializing in publicly traded companies and promising European ventures. For EPEI, acquiring a minority stake in Nanobacterie represents another step in implementing its new strategy. In addition to managing significant minority stakes in listed companies (primarily through VESA Equity Investment), EPEI invests in both majority and minority holdings, including private companies. Their key equity holdings include significant minority shares in publicly traded companies like International Distributions Services (Royal Mail), Sainsbury's, Fnac Darty, PostNL, Foot Locker, Quadient, and TF1. Through its subsidiary, France

30 April 2024



Retail Holdings, EPEI also recently acquired a controlling stake in Casino Guichard-Perrachon.